Longitudinal biomarkers after oesophagogastric cancer surgery
Research type
Research Study
Full title
The LABS Study: Longitudinal Assessment of Biomarkers after oesophagogastric cancer Surgery (BIORESOURCE 2: Longitudinal)
IRAS ID
320961
Contact name
George Hanna
Contact email
Sponsor organisation
Imperial College London
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. Our research group has already investigated the bacteria specific to oesophagogastric cancer and how its production of small molecules may be detected with a breath test.
Our BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched samples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and/or long term prognosis. Additional biosamples include tissue, breath, saliva, urine and blood. The bio fluids will be collected at multiple time points in the first year of follow-up (6 weeks, 3 months, 6 months and 1 year) to further investigate the metabolic pathways involved in cancer development and to determine mechanisms involved in chemotherapy and radiotherapy response along with predictive models of long-term prognosis.
REC name
North of Scotland Research Ethics Committee 1
REC reference
23/NS/0111
Date of REC Opinion
2 Oct 2023
REC opinion
Favourable Opinion